Hormone Refractory Prostate Cancer
34
0
1
19
Key Insights
Highlights
Success Rate
76% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
17.6%
6 terminated out of 34 trials
76.0%
-10.5% vs benchmark
12%
4 trials in Phase 3/4
47%
9 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (34)
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
Study Evaluating the Safety and Tolerability of L-377202
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
BAY88-8223, Does Response Study in HRPC Patients
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
Study of Weekly Cabazitaxel for Advanced Prostate Cancer
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Molecular Phenotype Changes and Personalized Treatment for CRPC